Prof. Dan Shechtman of the Technion–Israel Institute of Technology made the discovery that would later earn him the 2011 ...
A Korean research team has succeeded in securing a basic technology for further improving the completeness level of ...
Farxiga (dapagliflozin) is an orally administered, brand-name medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 inhibitors help lower blood sugar by causing the ...
Dapagliflozin plus calorie restriction beneficial for patients with overweight or obesity and type 2 diabetes. (HealthDay News) — For patients with overweight or obesity and type 2 diabetes ...
It took a while for scientists to gain access to the samples that NASA’s OSIRIS-REx mission took from the asteroid Bennu, but the wait is proving to be worth it. A new study published January 29 in ...
Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...
Diabetes remission was achieved in 44% and 28% of patients in the dapagliflozin and placebo groups, respectively, over 12 months, meeting the predefined primary end point. Yuejun Liu, from Fudan ...
Two spiraling structures come together to create the Solomon R. Guggenheim Museum, Frank Lloyd Wright’s midcentury masterpiece on Manhattan’s Upper East Side. Wright chose the circular shape ...
In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...
Interventions Calorie restriction with dapagliflozin 10 mg/day or placebo. Main outcome measures Primary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback